Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Abstract

Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression. The enzalutamide group had a higher incidence of seizures and other toxic effects, especially among those treated with early docetaxel. (Funded by Astellas Scientific and Medical Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ACTRN12614000110684; ClinicalTrials.gov number, NCT02446405; and EU Clinical Trials Register number, 2014-003190-42.).

Keywords

EnzalutamideMedicineHazard ratioProstate cancerClinical endpointInternal medicineOncologyDocetaxelAdverse effectProgression-free survivalDiscontinuationAndrogen deprivation therapyAntiandrogenConfidence intervalRandomized controlled trialCancerAndrogen receptorOverall survival

MeSH Terms

AdenocarcinomaAgedAndrogen Receptor AntagonistsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBone NeoplasmsDigestive System NeoplasmsFatigueFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedNitrilesPhenylthiohydantoinProgression-Free SurvivalProstatic NeoplasmsSeizures

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Publication Info

Year: 2019
Type: article
Volume: 381
Issue: 2
Pages: 121-131
Citations: 1481
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1481

OpenAlex

Influential

1301

CrossRef

Cite This

APA Style

                            
                                
                                    Ian D. Davis, 
                                
                                    Andrew Martin, 
                                
                                    Martin R. Stockler
                                
                                et al.
                            
                            (2019). 
                            Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. 
                            New England Journal of Medicine
                            , 381
                            (2)
                            , 121-131.
                            https://doi.org/10.1056/nejmoa1903835
                        

Identifiers

DOI: 10.1056/nejmoa1903835
PMID: 31157964

Data Quality

Data completeness: 90%